Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-06-15
1998-09-22
Allen, Marianne P.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
536 235, 435 691, 4353201, 435325, 530350, 530399, 530324, C12N 1518, A61K 3818, C07K 14475
Patent
active
058113932
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This invention relates to growth factors.
Growth factors play a central role in mediating cell proliferation and differentiation, for example, basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), transforming growth factor-alpha (TGF-.alpha.), and transforming growth factor-beta (TGF-.beta.) have been implicated in the proliferation of connective tissue cells and the induction of angiogenesis characteristic of wound repair (Van Brunt and Klausner, 6 Biotechnology 25, 1988). In addition, Agel et al. (146 J. Pathol. 197, 1985) suggest that growth factors are involved in the etiology of atherosclerosis; for example, the smooth muscle cell (SMC) hyperplasia that accompanies atherosclerosis has been attributed to PDGF, a potent SMC mitogen.
Heparin affinity chromatography has been used extensively for purifying and characterizing a variety of these growth factors. Acidic FGF (aFGF) and basic FGF (bFGF) bind to immobilized heparin columns and are eluted with 1.0M to 1.2M NaCl and 1.5M to 1.8M NaCl, respectively (Folkman and Klagsbrun, 235 Science 442, 1987; Lobb et al., 261 J. Biol. Chem. 1924, 1986). Several growth factors which are structurally homologous to aFGF and bFGF also have an affinity for heparin (see, for example, Rubin et al., 86 Proc. Natl. Acad. Sci. USA 802, 1989). PDGF binds to immobilized heparin, but with relatively low affinity, being eluted with only 0.5M NaCl. Epidermal growth factor (EGF) does not bind heparin to any substantial extent under the conditions described in the cited references on heparin binding growth factors. Lobb et al. (261 J. Biol. Chem. 1924, 1986) report the partial purification by heparin affinity of two classes of growth factors mitogenic for endothelial cells. Gospodarowicz et al. (81 Proc. Natl. Acad. Sci. USA 6963, 1984) report the use of heparin affinity in the purification of bovine brain and pituitary fibroblast growth factors. Shing et al. (29 J. Cell Biochem. 275, 1985) report a chondrosarcoma-derived growth factor purified by heparin-Sepharose affinity chromatography and Bio Rex 70 cation exchange chromatography. Bohlen et al. (185 FEBS Lett. 177, 1985) report a fibroblast growth factor, derived from human brain, which is purified by cation-exchange chromatography, heparin-Sepharose affinity, and reverse-phase HPLC. Shing et al. (223 Science 1296, 1984) report a heparin-binding tumor cell-derived capillary endothelial cell factor. Besner et al. (107 J. Cell Biol. 481a, 1988) report the detection of a heparin-binding, mononuclear cell-derived growth factor(s) which is cationic, is of 6000-14,000 MW, is inactivated by heat (100.degree. C., 10 min), is inactivated by dithiothreitol (5 mM), and is resistant to incubation with 4M guanidine or 0.1M HCl.
SUMMARY OF THE INVENTION
In one aspect, the invention generally features a novel growth factor which we have termed heparin binding EGF-homologous mitogen (HB-EHM). By "EGF homologous" is meant having a segment structurally related to epidermal growth factor in that it contains six cysteine residues spaced in a manner characteristic of any of the EGF family of proteins (e.g., human amphiregulin (AR), Shoyab et al., 243 Science 1074, 1989; human TGF-.alpha., Derynck et al., 38 Cell 287, 1984; and human EGF, Gregory, 257 Nature 325, 1975), which participates in binding as described below to one or more of the EGF family of receptors (e.g., on A-431 cells or smooth muscle cells). In general, an EGF-homologous segment renders the protein including such a domain at least partially resistant to heat (e.g., following exposure to a temperature of 90.degree. for 5 minutes) and sensitive to dithiothreitol (DTT) (e.g., following exposure to 5 mM DTT for 2 hours). "Heparin binding" means having a specific affinity for heparin (i.e., an affinity beyond that predicted only by ionic interactions) as evidenced by binding to heparin at NaCl concentrations above those which elute similarly charged proteins having no specific affinity. In general, heparin binding factors remain
REFERENCES:
Besner, G. et al., Cell Regulation, 1:811-19, Oct. 1990.
Besner, G. et al., J. Cell Biology, 6 (Part 3): 481a, abstract 2706, 1988 (29 Jan.-2 Feb. 1989 meeting).
Lupu et al., Science, 269:1552-1555, 1990, "Direct Interaction of a ligand for the erb82 Oncogene Product with the EGF Receptor and p185.sup.erb82."
Madtas et al., Cell, 53:285-283, 1988, "Induction of Transforming Growth Factor-.alpha. in Activated Human Alveolar Macrophages."
Assoian et al., Proc. Natl. Acad. Sci., 84:6020-6024, 1987, "Expression and Secretion of type .beta. Transforming Growth Factor by Activated Human Macrophages."
Hazuda et al., The Journal of Biological Chemistry, 263:8473-8479, 1988, "The Kinetics of Interlukin 1 Secretion form Activated Monocytes."
Schmidt et al., The Journal of Clinical Investigation, Inc., 73:1462-1472, 1984, "Silicon-stimulated Monocytes Release Fibroblast Proliferation Factors Identical to Interleukin 1."
Leibovich, Nature, 329:630-632, 1987, "Macrophage-induced angiogenesis is mediated by tumour necrosis factor-.alpha.."
Singh et al., Proc. Nat'l Acad. Sci, 85:6374-6378, 1988, "Purification and biochemical properties of a human monocyte-derived growth factor."
Nathan, Journal of Clinical Investigation, 79:319-326, 1987, "Secretory Products of Macrophages."
Van Brunt and Klausner, Biotechnology, 6:25-30, 1988, "Growth Factors Speed Wound Healing."
Agel et al., J. Pathol., 146:197-204, 1985, "Identification of Macrophages and Smooth Muscle Cells in Human Atherosclerosis Using Monoclonal Antibodies."
Folkman and Klagsbrun, Science 235:397-442, 1987, "Angiogenic Factors."
Lobb et al., J. Biol. Chem., 261:1924-1928, 1986, "Purification and Characterization of Heparin-binding Endothelial Cell Growth Factors."
Rubin et al. Proc. Natl. Acad. Sci. USA, 86:802-806, 1989, "Pufification and characterization of newly identified growth factor specific for epithelial cells."
Gospodarowicz et al., Proc. Natl. Sci. USA, 81:6963-6967,1984, "Isolation of brain fibroblast growth factor by heparin-Sepharose affinity chromatography: Identity with pituitary fibroblast growth factor."
Shing et al., J. Cell Biochem. 29:275-287, 1985, "Angiogenesis Is Stimulated by a Tumor-Derived Endothelial Cell Growth Factor."
Bohlen et al., Febs Lett., 185:177-181, 1985, "Human brain fibroblast growth factor."
Shing et al., Science, 223:1296-1298, 1984, "Heparin Affinity: Purification of a Tumor-Derived Capillary Endothelial Cell Growth Factor."
Shoyab et al., Science, 243: 1074-1076, 1989, "Structure and Function of Human Amphiregulin: A Member of the Epidermal Growth Factor Family."
Derynck et al., Cell, 38:287-297, 1984, "Human Transforming Growth Factor-.alpha.: Precursor Structure and Expression in E. coli."
Gregory, Nature, 257:325-327, 1975, "Isolation and structure of urogastrone and its relationship to epidermal growth factor."
Suggs et al., Proc. Natl. Acad. Sci. USA, 78:6613-6617, 1981, "Use of synthetic oligonucleotides as hybridization probes: Isolation of cloned cDNA sequences for human .beta..sub.2 -microglobulin."
Abraham Judith A.
Besner Gail E.
Higashiyama Shigeki
Klagsbrun Michael
Allen Marianne P.
Scios Nova Inc.
The Children's Medical Center Corp.
LandOfFree
Heparin binding mitogen with homology to epidermal growth factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heparin binding mitogen with homology to epidermal growth factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heparin binding mitogen with homology to epidermal growth factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1621800